Brad Kahl, MD

Articles

Dr Kahl on Ongoing and Planned Investigations Within the Landscape of MCL

October 5th 2023

Brad S. Kahl, MD, discusses ongoing and planned investigations within the landscape of mantle cell lymphoma.

Dr. Kahl on the Current Unmet Needs in MCL

July 26th 2022

Brad S. Kahl, MD, discusses unmet needs in mantle cell lymphoma.

Dr. Kahl on the Potential of Zanubrutinib in the Frontline Treatment of CLL

February 24th 2022

Brad S. Kahl, MD, discusses the potential for zanubrutinib in the frontline treatment of chronic lymphocytic leukemia.

Dr. Kahl on the Emergence of Antibody-Drug Conjugates in Lymphoma

August 11th 2021

Brad S. Kahl, MD, discusses the emergence of antibody-drug conjugates in lymphoma.

Dr. Kahl on Remaining Challenges in Indolent Non-Hodgkin Lymphoma

September 17th 2020

Brad S. Kahl, MD, discusses remaining challenges in the indolent non-Hodgkin lymphoma treatment landscape.

Dr. Kahl on the Current Treatment Landscape in Relapsed/Refractory iNHL

September 15th 2020

Brad S. Kahl, MD, discusses the current treatment landscape in relapsed/refractory indolent non-Hodgkin lymphoma.

Dr. Kahl on the Utility of Tafasitamab/Lenalidomide in DLBCL

July 14th 2020

Brad S. Kahl, MD, discusses the utility of tafasitamab combined with lenalidomide in patients with diffuse large B-cell lymphoma who are ineligible for CAR T-cell therapy.

Dr. Kahl on Efficacy of Targeted Agents in Relapsed/Refractory Indolent Lymphomas

April 15th 2020

Brad Kahl, MD, discusses the efficacy of targeted agents across indolent lymphomas.

Dr. Kahl on Treatment Strategies for Indolent Lymphoma

March 25th 2020

Brad Kahl, MD, discusses treatment strategies for patients with indolent lymphoma.

Dr. Kahl on BTK Inhibitor Time-Definite Trials in CLL

February 12th 2020

Brad Kahl, MD, discusses trials looking at time-definite therapy looking at BTK inhibitor combinations in chronic lymphocytic leukemia.

Dr. Kahl on Frontline BTK Inhibitor Selection in CLL

January 2nd 2020

Brad Kahl, MD, discusses choosing between BTK inhibitors ibrutinib and acalabrutinib for frontline treatment of chronic lymphocytic leukemia.

Dr. Kahl on Frontline Therapy Selection in CLL

February 7th 2019

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine, Siteman Cancer Center, discusses frontline therapy selection in chronic lymphocytic leukemia (CLL).

Dr. Kahl on Promising Research in Chronic Lymphocytic Leukemia

November 29th 2018

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine, Siteman Cancer Center, discusses exciting data on the horizon in chronic lymphocytic lymphoma (CLL).

Dr. Kahl on Considerations for Treatment Strategies in CLL

November 6th 2018

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine, Siteman Cancer Center, discusses considerations for treatment strategies in patients with chronic lymphocytic leukemia.

Dr. Kahl on Patient Preference in Treatment Selection for CLL

October 27th 2018

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine, Siteman Cancer Center, discusses patient preference in treatment selection for chronic lymphocytic leukemia.

Dr. Kahl on the Impact of Venetoclax in Chronic Lymphocytic Leukemia

October 25th 2018

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the impact of venetoclax (Venclexta) in the treatment of patients with chronic lymphocytic leukemia (CLL).

Dr. Kahl on Ibrutinib in CLL

October 19th 2018

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine, Siteman Cancer Center, discusses the use of ibrutinib (Imbruvica) in the treatment of patients with chronic lymphocytic leukemia (CLL).

Dr. Kahl Discusses the Construction of ADCs for Lymphoma Treatment

September 6th 2018

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the construction of antibody-drug conjugates for the treatment of patients with lymphoma.

Dr. Kahl Discusses Unmet Needs in MCL

August 28th 2018

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses unmet needs in the treatment landscape of mantle cell lymphoma.

Dr. Kahl on the Potential of CAR T-Cell Therapy in MCL

August 3rd 2018

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the potential of chimeric antigen receptor (CAR) T-cell therapy in mantle cell lymphoma (MCL).